Synthetically Modified Viral Capsids as Versatile Carriers for Use in Antibody-Based Cell Targeting.

The present study describes an efficient and reliable method for the preparation of MS2 viral capsids that are synthetically modified with antibodies using a rapid oxidative coupling strategy. The overall protocol delivers conjugates in high yields and recoveries, requires a minimal excess of antibody to achieve modification of more than 95% of capsids, and can be completed in a short period of time. Antibody-capsid conjugates targeting extracellular receptors on human breast cancer cell lines were prepared and characterized. Notably, conjugation to the capsid did not significantly perturb the binding of the antibodies, as indicated by binding affinities similar to those obtained for the parent antibodies. An array of conjugates was synthesized with various reporters on the interior surface of the capsids to be used in cell studies, including fluorescence-based flow cytometry, confocal microscopy, and mass cytometry. The results of these studies lay the foundation for further exploration of these constructs in the context of clinically relevant applications, including drug delivery and in vivo diagnostics.

[1]  de Goeij,et al.  Antibody-drug conjugates in cancer , 2016 .

[2]  Allie C. Obermeyer,et al.  Multivalent Viral Capsids with Internal Cargo for Fibrin Imaging , 2014, PloS one.

[3]  R. Chari,et al.  Antibody-drug conjugates: an emerging concept in cancer therapy. , 2014, Angewandte Chemie.

[4]  O. Farokhzad,et al.  Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology , 2014 .

[5]  A. Pandit,et al.  Polymer-antibody fragment conjugates for biomedical applications , 2014 .

[6]  P. Trail.  Antibody Drug Conjugates as Cancer Therapeutics , 2013 .

[7]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[8]  M. Francis,et al.  Controlled integration of gold nanoparticles and organic fluorophores using synthetically modified MS2 viral capsids. , 2013, Journal of the American Chemical Society.

[9]  J. O’Neil,et al.  PET Imaging and biodistribution of chemically modified bacteriophage MS2. , 2013, Molecular pharmaceutics.

[10]  Corwin M. Nycholat,et al.  Glycan-targeted virus-like nanoparticles for photodynamic therapy. , 2012, Biomacromolecules.

[11]  Horst Kessler,et al.  Guiding plant virus particles to integrin-displaying cells. , 2012, Nanoscale.

[12]  Allie C. Obermeyer,et al.  Rapid chemoselective bioconjugation through oxidative coupling of anilines and aminophenols. , 2011, Journal of the American Chemical Society.

[13]  M. Francis,et al.  Multivalent, high-relaxivity MRI contrast agents using rigid cysteine-reactive gadolinium complexes. , 2011, Journal of the American Chemical Society.

[14]  Sean C. Bendall,et al.  Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.

[15]  M. Schenerman,et al.  Advances in the assessment and control of the effector functions of therapeutic antibodies , 2011, Nature Reviews Drug Discovery.

[16]  N. Stephanopoulos,et al.  Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. , 2010, ACS nano.

[17]  Louis M. Weiner,et al.  Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.

[18]  M. Young,et al.  Targeted Delivery of a Photosensitizer to Aggregatibacter actinomycetemcomitans Biofilm , 2010, Antimicrobial Agents and Chemotherapy.

[19]  Sonny C. Hsiao,et al.  Genome-free viral capsids as multivalent carriers for taxol delivery. , 2009, Angewandte Chemie.

[20]  Sonny C. Hsiao,et al.  Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. , 2009, Journal of the American Chemical Society.

[21]  O. Ornatsky,et al.  Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. , 2009, Analytical chemistry.

[22]  Kristi L Kiick,et al.  Polymer-Based Therapeutics. , 2009, Macromolecules.

[23]  Monty Liong,et al.  Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. , 2008, ACS nano.

[24]  M. Francis,et al.  Oxidative coupling of peptides to a virus capsid containing unnatural amino acids. , 2008, Chemical communications.

[25]  D. Toomre,et al.  Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: a novel anti-epidermal growth factor receptor antibody. , 2007, Neoplasia.

[26]  Marianne Manchester,et al.  Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. , 2007, Chemistry & biology.

[27]  D. Hicklin,et al.  Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. , 2007, Anticancer research.

[28]  Guohua Zhang,et al.  Polymer-based elemental tags for sensitive bioassays. , 2007, Angewandte Chemie.

[29]  Jacob M Hooker,et al.  Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. , 2007, Bioconjugate chemistry.

[30]  Sek-Man Wong,et al.  Folic acid-conjugated protein cages of a plant virus: a novel delivery platform for doxorubicin. , 2007, Bioconjugate chemistry.

[31]  M. Francis,et al.  Modification of aniline containing proteins using an oxidative coupling strategy. , 2006, Journal of the American Chemical Society.

[32]  Trevor Douglas,et al.  Viruses: Making Friends with Old Foes , 2006, Science.

[33]  Trevor Douglas,et al.  Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. , 2006, Chemistry & biology.

[34]  Donald A Tomalia,et al.  Dendrimers in biomedical applications--reflections on the field. , 2005, Advanced drug delivery reviews.

[35]  Francis C Szoka,et al.  Designing dendrimers for biological applications , 2005, Nature Biotechnology.

[36]  B. Burtness,et al.  Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. , 2005, Drugs of today.

[37]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[38]  M. Young,et al.  Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. , 2005, Chemical communications.

[39]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[40]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[41]  Andrew B. Martin,et al.  Generation of a bacterium with a 21 amino acid genetic code. , 2003, Journal of the American Chemical Society.

[42]  Chris J. Adams,et al.  RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation , 2003, Intervirology.

[43]  John E. Johnson,et al.  Natural supramolecular building blocks. Wild-type cowpea mosaic virus. , 2002, Chemistry & biology.

[44]  J. Mendelsohn,et al.  Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. , 1994, The Journal of biological chemistry.

[45]  C. Macleod,et al.  Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[46]  M. Francis,et al.  Synthetically modified Fc domains as building blocks for immunotherapy applications , 2013 .

[47]  R. Tiwari,et al.  Drug delivery systems: An updated review , 2012, International journal of pharmaceutical investigation.

[48]  Adriana L. Gonzalez,et al.  Epidermal growth factor receptor (EGFR) antibody down-regulates mutant receptors and inhibits tumors expressing EGFR mutations. , 2006, The Journal of biological chemistry.

[49]  B. Burtness,et al.  An epidermal growth factor receptor chimeric human-murine monoclonal antibody , 2005 .